Paul R. Edick - 31 Jan 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chairman and Chief Executive Officer, Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
31 Jan 2024
Net transactions value
$0
Form type
4
Filing time
31 Jan 2024, 17:04:32 UTC
Previous filing
09 Aug 2023
Next filing
04 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +1,500,000 +66% $0.000000 3,788,064 31 Jan 2024 Direct F1
holding XERS Common Stock 33,430 31 Jan 2024 By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Appreciation Right Award $0 +500,000 $0.000000 500,000 31 Jan 2024 Common Stock 500,000 $2.46 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 The award will vest in full on the two-year anniversary of the grant date.
F4 Upon exercise, the Stock Appreciation Right will be settled in cash.

Remarks:

Chairman and Chief Executive Officer